InsidersTradesSigma
Track the 广誉远 share price and the full directors' dealings record of the company, a listed equity based in China. Shares are quoted on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 广誉远 has published 6 reports. Market capitalisation: €7.2bn. The latest transaction was reported on 1 April 2026 (Purchase). Among the most active insiders: 徐智麟. The full history is free.
6
Insider Decl.
n/a
Thresholds
€25,239
2 ops.
Buy Volume
€111,517
4 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 16,629 of 29,062 companies
47.9
score / 100
Value31
Quality64
FCF yld2.7%
Earn yld0.9%
EV/EBITDA47.0x
ROE4.0%
Gross mgn68%
Net mgn4.6%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 April 2026
Declarations6 total
6 of 6 declarations
About 广誉远
广誉远 is a company in the health and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the research and development of traditional Chinese pharmaceutical products.